Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen R Johnston

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Breast Cancer Research and Treatment|October 26, 2005
Fulvestrant ('Faslodex'): extending the reach of endocrine therapy?Stephen R Johnston
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Controversies in adjuvant endocrine therapy for breast cancerStephen R Johnston
Expert Opinion on Emerging Drugs|November 13, 2003
Protein farnesyltransferase inhibitorsJulia E Head, Stephen R Johnston
Breast Cancer Research and Treatment|October 26, 2005
Endocrine therapy--current benefits and limitationsRobert I Nicholson, Stephen R Johnston
Breast Cancer Research and Treatment|October 26, 2005
Life following aromatase inhibitors--where now for endocrine sequencing?Stephen R Johnston, Lesley-Ann Martin, Mitch Dowsett
Journal of Cellular Biochemistry|July 29, 2010
Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancerRebecca A Burrell, Nicolai Juul, Stephen R Johnston, et al.
Plos One|June 17, 2016
Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated TransactivationStephanie K Guest, Ricardo Ribas, Sunil Pancholi, et al.
British Journal of Cancer|July 12, 2018
Abiraterone shows alternate activity in models of endocrine resistant and sensitive diseaseNikiana Simigdala, Sunil Pancholi, Ricardo Ribas, et al.
Cancer Chemotherapy and Pharmacology|March 19, 2009
A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancerOlivier Rixe, Sandra X Franco, Denise A Yardley, et al.
Acta Oncologica (Stockholm, Sweden)|March 21, 2006
Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumabThomas Yau, Charles Swanton, Sue Chua, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Breast Cancer Research and Treatment|October 26, 2005
Fulvestrant ('Faslodex'): extending the reach of endocrine therapy?Stephen R Johnston
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Controversies in adjuvant endocrine therapy for breast cancerStephen R Johnston
Expert Opinion on Emerging Drugs|November 13, 2003
Protein farnesyltransferase inhibitorsJulia E Head, Stephen R Johnston
Breast Cancer Research and Treatment|October 26, 2005
Endocrine therapy--current benefits and limitationsRobert I Nicholson, Stephen R Johnston
Breast Cancer Research and Treatment|October 26, 2005
Life following aromatase inhibitors--where now for endocrine sequencing?Stephen R Johnston, Lesley-Ann Martin, Mitch Dowsett
Journal of Cellular Biochemistry|July 29, 2010
Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancerRebecca A Burrell, Nicolai Juul, Stephen R Johnston, et al.
Plos One|June 17, 2016
Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated TransactivationStephanie K Guest, Ricardo Ribas, Sunil Pancholi, et al.
British Journal of Cancer|July 12, 2018
Abiraterone shows alternate activity in models of endocrine resistant and sensitive diseaseNikiana Simigdala, Sunil Pancholi, Ricardo Ribas, et al.
Cancer Chemotherapy and Pharmacology|March 19, 2009
A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancerOlivier Rixe, Sandra X Franco, Denise A Yardley, et al.
Acta Oncologica (Stockholm, Sweden)|March 21, 2006
Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumabThomas Yau, Charles Swanton, Sue Chua, et al.
Pageof 2